Joyce Chou

8PUBLICATIONS
40CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsBasic pharmacology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Aug 25, 2025
Efficacy and safety of one-time autologous tumor-infiltrating lymphocyte cell therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.

Robert L Ferris, Rom S Leidner, Christine H Chung

|Jun 02, 2025
Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients With Advanced Melanoma: A 5-Year Analysis of the C-144-01 Study.

Theresa Medina, Jason A Chesney, Harriet M Kluger

|Oct 27, 2022
First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors.

Omid Hamid, Alberto A Chiappori, John A Thompson

|Oct 25, 2021
Association of Tumor Mutational Burden and Immune Gene Expression with Response to PD-1 Blockade by Sasanlimab Across Tumor Types and Routes of Administration.

Siwen Hu-Lieskovan, Fadi Braiteh, Juneko E Grilley-Olson

|Oct 07, 2021
A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers.

Adi Diab, Omid Hamid, John A Thompson

|Jan 21, 2021
Addressing resistance to immune checkpoint inhibitor therapy: an urgent unmet need.

Siwen Hu-Lieskovan, Gabriel G Malouf, Ira Jacobs

Pageof 2

Frequent Collaborators

3 joint publications

Omid Hamid

2 joint publications

Christopher R Kimberlin

2 joint publications

Christopher P Dillon

2 joint publications

Juneko E Grilley-Olson